On January 11, 2026, FDA’s Center for Biologics Evaluation and Research (CBER) posted a statement describing the agency’s “flexible approach” to chemistry, manufacturing, and controls (CMC) oversight for cell and gene therapy (CGT) products. The posting did not create new legal requirements — FDA was explicit that it “did not change the legal requirements with respect to CMC for CGTs” — but it consolidated and made public, in one place, flexibilities CBER review staff had already been applying case by case. Two follow-on regulatory actions since have turned that January posture into something more durable, and this page tracks all three as one continuous development rather than a single isolated announcement.
What FDA actually said on January 11, 2026
The core of the announcement is that CGT products — often autologous, individualized, made in small batches with short shelf lives and inherently limited manufacturing history — don’t fit cleanly into CMC expectations built around small-molecule and conventional biologic manufacturing. FDA described several specific areas of flexibility available to sponsors developing a CGT product toward a Biologics License Application (BLA):
- No cGMP requirement before Phase 2/3. Sponsors are not required to manufacture under full current Good Manufacturing Practice (cGMP) compliance for early-phase (Phase 1) investigational lots. This tracks the existing phase-appropriate GMP concept already codified for INDs generally at 21 CFR 210.2(c) and FDA’s 2008 “CGMP for Phase 1 Investigational Drugs” guidance, applied here specifically to CGT products moving toward later-phase trials.
- Permissive product-quality/release criteria. FDA said it will consider flexibility in release and commercial specifications for CGT BLAs — including tailoring acceptance criteria to what’s actually achievable at a given development stage, and considering sponsor requests to revise release specifications later, based on post-approval manufacturing experience rather than requiring everything locked pre-approval.
- Risk-based comparability. When manufacturing changes (site, scale, process) occur during development, FDA signaled a risk-based approach to comparability testing rather than a fixed, one-size checklist.
- Process validation and lot flexibility. FDA clarified there is no requirement to manufacture three process performance qualification (PPQ) lots — a convention carried over from conventional biologics manufacturing. Review will instead assess whether a sponsor’s PPQ protocol justifies its own proposed number of lots, and FDA said it will consider concurrent release of PPQ lots for commercial use after BLA approval, provided those lots meet commercial release specifications.
- Use of prior knowledge and consensus standards. The announcement also flagged that sponsors can lean on prior scientific/manufacturing knowledge (their own, or from analogous products) during CMC development, and can use voluntary consensus standards where applicable, rather than generating every data point from scratch for each new product.
Timeline: from a web posting to a finalized guidance to a genome-editing-specific framework
This is where treating January 11 as a single, closed event undersells what’s actually happened this year:
- January 11, 2026 — CBER posts the flexible-approach statement described above, on FDA’s cellular and gene therapy products site. Framed as clarifying existing practice, not a new formal guidance document.
- May 8, 2026 — FDA finalizes a formal guidance document, effective immediately, that codifies the same set of flexibilities into an actual guidance: phase-appropriate cGMP, release criteria tailored to development stage, risk-based comparability, prior-knowledge use, voluntary consensus standards, scientifically-justified PPQ lot numbers (rather than a fixed three), concurrent PPQ-lot release for commercial use, commercial specifications supportable by fewer or single representative lots, use of clinical-lot stability data to support commercial expiration dating, and allowance for alternative analytical methods that reduce sample volume or testing time.
- June 2, 2026 — FDA publishes a separate draft guidance addressing how sponsors can leverage prior CMC, nonclinical, and clinical knowledge specifically for gene therapy products incorporating ex vivo or in vivo human genome editing. This is the genome-editing-specific “knowledge reuse” piece: rather than each genome-edited product regenerating a full CMC and nonclinical safety package from zero, the draft guidance describes how relevant prior knowledge — the analyst’s own platform experience, or public/consortium data on a given editing modality — can be leveraged and referenced. As of this writing it remains in draft, not finalized; treat any description of its final scope as provisional until FDA closes the comment period and issues a final version.
Regulatory-affairs coverage (RAPS/Regulatory Focus) has characterized the direction as putting into writing what CBER review divisions were already doing informally in practice, rather than lowering the underlying evidentiary bar for safety and efficacy.
Why this matters for CGT development
FDA’s own stated rationale is that “traditional product development strategies” are a poor fit for CGT products: individualized or autologous manufacturing, small eligible patient populations, correspondingly few manufacturing runs to characterize a process against, and shorter product shelf lives that make classic three-lot PPQ validation impractical. Each of the flexibilities above targets one of those specific mismatches rather than a general relaxation of CMC standards. For sponsors and the research-administration teams supporting IND/BLA-track CGT programs, the practical effect is fewer places where a program stalls waiting to generate data that a comparable conventional biologic would have needed, but not a change to what FDA ultimately requires to support approval.
How this differs from CASRAI’s other FDA gene-therapy pages
This page is scoped narrowly to the CMC/manufacturing flexibility development described above. It is not a restatement of either of these related, but distinct, topics:
- FDA Approval for Gene Therapy: The BLA, CBER, and RMAT Pathway Explained covers the overall regulatory approval pathway — how a gene therapy product moves through IND to BLA, CBER’s review role, and the Regenerative Medicine Advanced Therapy (RMAT) designation, which accelerates clinical review timelines (expedited interactions, potential for rolling review) rather than adjusting CMC/manufacturing expectations.
- FDA Platform Technology Designation Program: Eligibility and How It Speeds Manufacturing Changes covers a separate, formal statutory designation (created by the 2022 FDORA amendments) that lets a sponsor reference prior manufacturing/CMC data across multiple products built on the same designated platform technology. The January 2026 CMC flexibility announcement is not a designation program at all — it requires no formal application or agency determination, and it applies generally to CGT product development rather than only to sponsors of a specific designated platform.
In short: RMAT speeds clinical review; Platform Technology Designation lets a specific designated platform’s sponsors reuse prior manufacturing data across products; the January 2026 CMC flexibility posture (and its May/June 2026 follow-through) adjusts the baseline CMC expectations — cGMP timing, specification rigidity, comparability testing, and lot-validation requirements — that apply to CGT development generally.
Frequently asked questions
Is the January 2026 CMC flexibility announcement a binding guidance document?
The January 11, 2026 posting itself was a web statement describing existing agency practice, not a formal guidance document, and FDA said it did not change any legal requirement. FDA subsequently finalized a formal guidance document on May 8, 2026 that codifies the same flexibilities with immediate effect — that document, not the January posting, is the citable guidance for sponsors preparing a submission.
Does this mean cGMP compliance is no longer required for cell and gene therapy manufacturing?
No. Full cGMP compliance is still expected by the time a product reaches later-phase (Phase 2/3) trials and commercial manufacturing. The flexibility applies to earlier-phase investigational manufacturing, consistent with the phase-appropriate GMP concept already established for INDs generally.
Does the genome-editing knowledge-reuse framework apply to all cell and gene therapies?
No. The June 2, 2026 draft guidance is scoped specifically to gene therapy products incorporating ex vivo or in vivo human genome editing, not to cell and gene therapy products generally. It remains in draft status.
Who should be tracking this development?
CMC/regulatory affairs staff, research administrators supporting IND/BLA-track CGT programs, and manufacturing/quality teams preparing process validation and specification-setting strategy for a CGT BLA submission.
Sources
- FDA, “Flexible Requirements for Cell and Gene Therapies to Advance Innovation” (posted January 11, 2026), fda.gov, Vaccines, Blood & Biologics — Cellular & Gene Therapy Products section.
- FDA, “Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application,” finalized guidance, May 8, 2026, fda.gov/regulatory-information/search-fda-guidance-documents.
- FDA draft guidance on leveraging prior CMC/nonclinical/clinical knowledge for human genome-editing gene therapy products, published June 2, 2026 (draft, comment period status should be re-checked before citing as final).
- Covington & Burling LLP, “FDA Announces a ‘Flexible Approach’ on Chemistry, Manufacturing and Control for Cell and Gene Therapies” (January 2026 client alert).
- Regulatory Affairs Professionals Society (RAPS), “FDA finalizes guidance on CMC flexibilities for cell and gene therapies,” Regulatory Focus.
